FDA ta amince da ibrutinib don maganin cututtukan cututtuka na yau da kullum (cGVHD) a cikin yara.

A ranar 24 ga Agusta, 2022, Hukumar Kula da Abinci da Magunguna ta Amurka (FDA) ta amince da ibrutinib don kula da marasa lafiyar yara waɗanda suka girmi shekara 1 tare da cututtukan da ba a taɓa gani ba (cGVHD) waɗanda ke karɓar Bayan gazawar 1- ko layi da yawa. tsarin jiyya .Alamar da aka yarda ta fi dacewa ga marasa lafiya na yara, tare da ƙimar amsa gabaɗaya na 60% a mako na 25, kuma ƙirar magungunan sun haɗa da capsules, allunan da dakatarwar baki.

Ibrutinib , mai hanawa na BTK wanda Pharmacyclics / Johnson & Johnson suka haɓaka, shine mai hana kinase wanda aka amince da shi a baya don maganin cutar sankarar lymphocytic na kullum da kuma lymphoma cell da sauran cututtuka.

Suntech yana mai da hankali kan haɓakawa da samar da matsakaicin magunguna da APIs ta amfani da fasahar kore.A halin yanzu, kamfaninmu ya haɓaka samfuran matsakaici guda uku na ibrutinib ciki har da C AS: 143900-44-1, C AS: 330792-70-6, C AS: 330786-24-8, duk waɗanda aka yi ciniki a cikin masana'antar GMP. .Daga cikin su, tsaka-tsakin C AS: 143900-44-1 an samar da shi ta hanyar fasaha na sinadaran-enzymatic , wanda ke da amfani na kare muhalli na kore, ƙananan farashi da inganci.Maraba don tuntuɓar da haɗin kai!